Cargando…

Quality of Life, Safety and Efficacy Profile of Thermostable Flolan in Pulmonary Arterial Hypertension

BACKGROUND: Flolan (epoprostenol sodium) is most commonly prescribed to patients with severe pulmonary arterial hypertension (PAH) owing to the requirement that the drug be delivered by continuous intravenous infusion and the reconstituted solution may only be administered up to 24 hours when it is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Provencher, Steeve, Paruchuru, Patrap, Spezzi, Andrea, Waterhouse, Brian, Gomberg-Maitland, Mardi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368561/ https://www.ncbi.nlm.nih.gov/pubmed/25793960 http://dx.doi.org/10.1371/journal.pone.0120657

Ejemplares similares

Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)—An open-label, single-arm study
por: Mihara, Kazuko, et al.
Publicado: (2018)

Takotsubo cardiomyopathy after treatment of pulmonary arterial hypertension
por: Cork, David P., et al.
Publicado: (2012)

Right Heart Catheterization—To Do or Not To Do? Introducing a New Diagnostic Algorithm for Pulmonary Hypertension
por: Ryan, John J., et al.
Publicado: (2022)

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic
por: Ryan, John J., et al.
Publicado: (2020)

Assessment of Daily Life Physical Activities in Pulmonary Arterial Hypertension
por: Mainguy, Vincent, et al.
Publicado: (2011)

Clinical trial design and new therapies for pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2019)

The cancer theory of pulmonary arterial hypertension
por: Boucherat, Olivier, et al.
Publicado: (2017)

Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
por: Lajoie, Annie-Christine, et al.
Publicado: (2017)

Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study
por: Feldman, Jeremy P., et al.
Publicado: (2021)

Signal transduction in the development of pulmonary arterial hypertension
por: Malenfant, Simon, et al.
Publicado: (2013)

Interpreting risk reduction in clinical trials for pulmonary arterial hypertension
por: Lajoie, Annie C., et al.
Publicado: (2018)

Computational platform for doctor–artificial intelligence cooperation in pulmonary arterial hypertension prognostication: a pilot study
por: Kheyfets, Vitaly O., et al.
Publicado: (2023)

Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil()
por: Piscoya Roncal, Carlos G., et al.
Publicado: (2019)

Pim-1: A new biomarker in pulmonary arterial hypertension
por: Renard, Sébastien, et al.
Publicado: (2013)

Alternatives to the Six-Minute Walk Test in Pulmonary Arterial Hypertension
por: Mainguy, Vincent, et al.
Publicado: (2014)

The role of late gadolinium enhancement of the right ventricular insertion point predicts survival in patients with pulmonary hypertension
por: Freed, Benjamin H, et al.
Publicado: (2011)

Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial
por: Gomberg-Maitland, Mardi, et al.
Publicado: (2019)

Fetal Gene Reactivation in Pulmonary Arterial Hypertension: GOOD, BAD, or BOTH?
por: Lemay, Sarah-Eve, et al.
Publicado: (2021)

Reply to Ning et al.: More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
por: Provencher, Steeve, et al.
Publicado: (2020)

Designing pulmonary arterial hypertension trials for detecting change in right ventricular function using cardiovascular magnetic resonance: what is the appropriate sample size?
por: Addetia, Karima, et al.
Publicado: (2013)

Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms
por: Malenfant, Simon, et al.
Publicado: (2021)

Health disparity is a global issue: Understanding Latin America
por: Gomberg‐Maitland, Mardi, et al.
Publicado: (2022)

DNA Damage and Pulmonary Hypertension
por: Ranchoux, Benoît, et al.
Publicado: (2016)

Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension
por: Malenfant, Simon, et al.
Publicado: (2020)

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023)

Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension
por: Freed, Benjamin H, et al.
Publicado: (2012)

Compromised Cerebrovascular Regulation and Cerebral Oxygenation in Pulmonary Arterial Hypertension
por: Malenfant, Simon, et al.
Publicado: (2017)

Author's reply
por: Cork, David P., et al.
Publicado: (2013)

Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension
por: Courboulin, Audrey, et al.
Publicado: (2011)

Role for miR-204 in human pulmonary arterial hypertension
por: Courboulin, Audrey, et al.
Publicado: (2011)

Identity crisis in pulmonary arterial hypertension
por: Ruffenach, G., et al.
Publicado: (2017)

Dual ET(A)/ET(B) blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension
por: Nadeau, Valerie, et al.
Publicado: (2017)

Reply to Chen et al.: BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
por: Provencher, Steeve, et al.
Publicado: (2020)

HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension
por: Boucherat, Olivier, et al.
Publicado: (2017)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
por: Monaco, Thomas J, et al.
Publicado: (2016)

COVID-19 and the pulmonary vasculature
por: Provencher, Steeve, et al.
Publicado: (2020)

Pulmonary hypertension and chronic lung disease: where are we headed?
por: Elia, Davide, et al.
Publicado: (2019)

Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension
por: Grobs, Yann, et al.
Publicado: (2021)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d8gm5cq50k1sq8730o119o1cp3